AONN+ Issues Statement on Clinical Trial Diversity Resources

News & Updates published on January 31, 2025 in News & Updates

STAT News recently published an article in response to the recent Executive Order removing federally backed Diversity, Equity, and Inclusion (DEI) initiatives, resulting in the removal of certain materials related to clinical trial diversity from the FDA website. Items no longer available include the National Institute of Health’s (NIH) Sexual & Gender Minority Research Office, the NIH Sexual & Gender Minority Health Scientific Research Group, and the Office of Research of Women’s Health web pages, among others.

The Academy of Oncology Nurse and Patient Navigators (AONN+) remains committed to supporting oncology navigators in their essential role of educating, empowering, and guiding patients through their cancer journey. Overcoming barriers to care, especially for patients in underserved areas, is a fundamental aspect of patient navigation. Our mission is to advance the role of patient navigation in cancer care across the care continuum by fostering a network for collaboration, leadership, and development of best practices for the improvement of patient access to care, evidence-based cancer treatment, and quality of life. AONN+ is dedicated to fostering effective navigation that ensures patient-focused, high-quality cancer care coordination from prediagnosis through survivorship/end-of-life. We are here to support our members, their patients, and the navigation community through these changing times.

Navigators are encouraged to continue leveraging the information and resources found in our Oncology Navigation Standards of Professional Practice, specifically:

  • Standard 4: Cultural and Linguistic Humility - Oncology navigators practice in a manner that is culturally and linguistically humble and inclusive
  • Standard 16: Advocacy - Oncology navigators advocate with and on behalf of patients, survivors, families, and caregivers to address their needs and goals (this is the one with reference to clinical trials)
  • Standard 12: Treatment, Care Planning, and Intervention - Oncology navigators provide support and information to patients and caregivers to navigate through all phases of active cancer treatment

The healthcare landscape is constantly shifting. AONN+ encourages its members to continue leveraging the strength of the navigation community we have created and the resources available through our organization to ensure that every patient receives the guidance and support they both need and deserve.

Related Items
Colorectal Cancer Screening Update: with Andi Dwyer, MPH
News & Updates published on June 23, 2026 in News & Updates
In this interview, AONN+ Board of Trustees member Andi Dwyer discusses the American Cancer Society’s updated colorectal cancer screening guidelines, including new stool-based tests and the first-ever recommendation of an FDA-approved blood-based screening test, while emphasizing that colonoscopy and stool tests remain the most effective tools for early detection and prevention.
AONN+ Joins Pfizer’s 7th Annual Advocacy Luncheon at ASCO 2026
News & Updates published on June 23, 2026 in News & Updates
Pfizer’s 7th Annual Advocacy Luncheon at ASCO 2026 brought together advocacy leaders, including AONN+ Executive Director Candice Roth, MSN, RN, CENP, to discuss emerging cancer therapies, the role of artificial intelligence in patient-centered care, and the launch of Pfizer’s new Patient Advocacy360 partnership framework.
AONN+ Takes Part in CAR T Vision Coalition Event
News & Updates published on June 23, 2026 in News & Updates
Candice Roth, MSN, RN, CENP, and Monica Dean represented AONN+ at the launch of the first U.S. CAR T Vision to Action Blueprint, a stakeholder-driven initiative that provides practical strategies and tools to address access barriers and expand the use of CAR T-cell therapy for eligible patients nationwide by 2030.